Krystal Biotech, Inc.

Total Valuation

Krystal Biotech, Inc. carries a market capitalization of 10.56B, placing it among publicly traded companies globally. Its enterprise value stands at 10.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Krystal Biotech, Inc. currently has 29.60M shares outstanding.

Valuation Ratios

Krystal Biotech, Inc. trades at a trailing price-to-earnings ratio of 44.97. The price-to-sales ratio is 24.65, and the price-to-book ratio stands at 8.09.

Enterprise Valuation

On an enterprise value basis, Krystal Biotech, Inc. trades at an EV/EBITDA multiple of 49.72 and an EV/FCF ratio of 35.42. The EV/Sales ratio of 23.07 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.39 provides insight into valuation relative to core operating earnings.

Financial Position

Krystal Biotech, Inc. maintains a current ratio of 8.32, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Krystal Biotech, Inc. has paid -14.85M in income taxes, reflecting an effective tax rate of 26.09.

Stock Price Statistics

Krystal Biotech, Inc.'s stock has gained approximately 146.72176% over the past 52 weeks. The 50-day moving average sits at 349.76, while the 200-day moving average is 290.32.

Income Statement

Over the trailing twelve months, Krystal Biotech, Inc. generated 440.48M in revenue and converted that into 241.47M in net income, yielding earnings per share of 7.97. EBITDA reached 204.42M, while operating income came in at 197.75M.

Balance Sheet

Krystal Biotech, Inc. holds 845.63M in cash and equivalents against 8.85M in total debt, resulting in a net debt position of -427.74M. Total book value stands at 1.36B, with working capital of 932.25M providing operational flexibility.

Cash Flow

Krystal Biotech, Inc. produced 272.34M in operating cash flow over the past twelve months. After subtracting -14.56M in capital expenditures, free cash flow totaled 257.78M - equivalent to 8.82 per share.

Margins

Krystal Biotech, Inc. operates with a gross margin of 94.64, reflecting its pricing power and cost economics. The operating margin of 44.89 and net profit margin of 54.82 provide insight into operational efficiency.

Dividends & Yields

Scores

Krystal Biotech, Inc. posts an Altman Z-Score of 48.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.